Director Philip Barach Injects $3.2M via Convertible Notes and Warrants
CELU has more than doubled off its 52-week low of $0.56.
Summary
Director and 10% owner Philip Barach bought $3.21 million of new convertible notes from Celularity, received 1.18 million warrants, and obtained options for up to $2.92 million more notes plus 1.46 million warrants. Existing notes and warrants were repriced to $1.50 and extended.
Key Events · Financing and Capital Events · CELU
-
Director Buys $3.21M Convertible Notes
Philip Alan Barach purchased $3,210,000 principal amount of new convertible notes from Celularity on September 23, 2026, convertible into 2,140,000 shares at $1.50 per share.
-
Warrants and Option for More Notes
Barach received 1,177,000 warrants with a $1.50 exercise price expiring September 23, 2031, and an option to purchase up to $2,915,531 of additional notes plus 1,457,765 warrants at $2.00 through September 30, 2027.
-
Existing Notes and Warrants Repriced
Existing convertible notes and warrants held by Barach were amended: conversion/exercise prices reduced from $1.66/$2.00 to $1.50, with maturities extended to September 23, 2028 and September 23, 2031.
-
Related-Party Financing Context
This financing follows a $1 million bridge loan from the Barach Family Trust in June 2026 and Nasdaq delisting notices in July 2026, indicating ongoing reliance on insider capital.
Analysis · CELU · Life Sciences
Philip Alan Barach, a director and 10% owner of Celularity, purchased $3.21 million of new convertible notes from the company on September 23, 2026, convertible into 2.14 million shares at $1.50 per share. He also received 1.18 million warrants with a $1.50 strike and an option to buy up to $2.92 million more notes plus 1.46 million warrants at $2.00 through September 2027. Existing notes and warrants were repriced down to $1.50 and extended to 2028 and 2031. This is a related-party financing that provides critical cash to a company that recently faced Nasdaq delisting notices and a $1 million bridge loan from the same family trust. The $1.50 conversion price sits above today's $1.38 stock price, meaning the new notes are not immediately in-the-money, but the repricing of existing securities to $1.50 and the large warrant overhang create meaningful potential dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.